Skip to Main Content

WASHINGTON — Medicare has already received more than 4,300 comments on its recent proposal to limit coverage for Biogen’s controversial Alzheimer’s drug Aduhelm, and other similar drugs. But most aren’t from drugmakers, Alzheimer’s advocacy groups, or even neurologists.

They’re from two unexpected letter writing campaigns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment